EP Patent

EP1598066A1 — Powder inhalant of sumatriptan and the method of preparation thereof

Assigned to Shanghai SIPI Pharmaceutical Co Ltd · Expires 2005-11-23 · 20y expired

What this patent protects

The invention relates to the powder inhalant of sumatriptan and the method of preparation thereof. The powder inhalant of sumatriptan of the invention comprises sumatriptan 5-90 wt%, colloidal adherent(s) 1-95%, water insoluble binder (s) 0-90 wt%, diluent(s) 0-94%, and surfactan…

USPTO Abstract

The invention relates to the powder inhalant of sumatriptan and the method of preparation thereof. The powder inhalant of sumatriptan of the invention comprises sumatriptan 5-90 wt%, colloidal adherent(s) 1-95%, water insoluble binder (s) 0-90 wt%, diluent(s) 0-94%, and surfactant(s) 0-2 wt%. The formulation of the invention can be used for the treatment of migraine. After the administration of drugs by nasal inhalation, the drugs absorbed through membrana mucosa nasi, and acted systematically. The formulation can be present in the form of a single dose of solid powder, which has an increased stability. All the powder absorbs through the cavity of nose, which leads to less amount of drugs remained in the delivery device, and which deposits on the sites more easily. Moreover, the formulation of the invention can be carried by the patients conveniently.

Drugs covered by this patent

Patent Metadata

Patent number
EP1598066A1
Jurisdiction
EP
Classification
Expires
2005-11-23
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai SIPI Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.